Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cranbury, NJ, Oct. 28, 2019 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing […]